Is Alexandria Real Estate Equities (ARE) Attractive After Recent Share Price Rebound?

• Investors may be wondering whether Alexandria Real Estate Equities is priced attractively today, or if the recent share price action has already reflected the value story.
• The stock last closed at US$53.12, with a 6.1% gain over the past week and a 21.3% gain over the past month, although the share price is still down 18.6% over the past year and 48.4% over three years.
• Recent headlines have focused on Alexandria Real Estate Equities as a specialised REIT in the life sciences and health care segment, and that context has kept investor attention on how its portfolio and funding profile compare with those of other property companies. At the same time, REITs linked to more specialised assets have featured in sector commentary, which helps frame how investors think about risk and required returns for this stock.
• On Simply Wall St’s valuation checks, Alexandria Real Estate Equities scores a 5 out of 6. The rest of this article explains what that score means across different valuation methods, and then offers a broader way to think about whether the current price aligns with your expectations.

Find out why Alexandria Real Estate Equities’s -18.6% return over the last year is lagging behind its peers.

Approach 1: Alexandria Real Estate Equities Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow model estimates what a stock could be worth by projecting its future adjusted funds from operations and discounting those cash flows back to today in dollar terms. For Alexandria Real Estate Equities, the model uses a two stage Free Cash Flow to Equity approach based on Adjusted Funds From Operations.

The latest twelve month free cash flow is reported at about $1.53b. Analysts provide forecasts out to 2029, with free cash flow for that year projected at $922.3m. Beyond those analyst inputs, Simply Wall St extrapolates further, with ten year projections ranging from about $834.7m in 2026 to $1.15b in 2035, each adjusted back to today using a discount rate.

Adding those discounted values and an estimated terminal value produces an intrinsic value estimate of $84.53 per share. Compared with the recent share price of $53.12, the model suggests Alexandria Real Estate Equities trades at about a 37.2% discount to this DCF estimate, which indicates a potentially attractive valuation based purely on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Alexandria Real Estate Equities is undervalued by 37.2%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Alexandria Real Estate Equities.

Approach 2: Alexandria Real Estate Equities Price vs Sales

For profitable companies and those with meaningful revenue, the P/S ratio can be a useful way to think about valuation because it compares what you pay for each dollar of sales, regardless of short term earnings swings.

In general, higher expected growth and lower perceived risk tend to justify a higher “normal” or “fair” P/S multiple, while slower growth and higher uncertainty usually line up with a lower multiple.

Alexandria Real Estate Equities currently trades on a P/S of 3.16x. That sits below the Health Care REITs industry average P/S of 6.48x and also below the peer group average of 5.26x. Simply Wall St’s Fair Ratio for the stock is 4.75x, which is an internally calculated view of what a reasonable P/S might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for the company’s own profile rather than assuming that all REITs in the same space deserve similar multiples.

With the Fair Ratio of 4.75x sitting above the current P/S of 3.16x, the stock screens as undervalued on this metric.

Result: UNDERVALUED

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Upgrade Your Decision Making: Choose your Alexandria Real Estate Equities Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple story that you create about Alexandria Real Estate Equities. This links your view on its life science portfolio, earnings path and risk profile to a concrete forecast and Fair Value that can be compared with the current share price.

On Simply Wall St’s Community page, Narratives let you plug in your assumptions for future revenue, margins and P/E, then translate that story into a Fair Value that sits alongside the live market price so you can judge for yourself whether the stock looks cheap or expensive given your expectations.

Narratives update automatically when fresh information such as earnings, impairments, dividend changes or analyst targets is added. This means the Fair Value that comes out of your story stays aligned with the latest data rather than a static spreadsheet.

For Alexandria Real Estate Equities, for example, one investor might align with a more optimistic Narrative that targets Fair Value around US$67.89, while another might lean toward a more cautious Narrative closer to US$50. Comparing both of those to the current price helps each investor decide whether the stock fits their own required return and risk tolerance.

For Alexandria Real Estate Equities, we will make it really easy for you with previews of two leading Alexandria Real Estate Equities Narratives:

🐂 Alexandria Real Estate Equities Bull Case

Fair value: US$88.00

Implied discount to fair value: 39.6%

Revenue growth assumption: 10.45%

• The bullish Narrative leans on a book NAV of about US$98 per share and concludes that, even after applying a margin of safety, intrinsic value sits well above the recent share price.
• It highlights Alexandria Real Estate Equities as a focused life science REIT with a concentrated portfolio in major research hubs, a sizeable development pipeline and exposure to tenants that are largely investment grade or publicly listed.
• It also flags key risks, including sector specific headwinds, occupancy pressure, rising financing costs and a recent dividend cut, but still frames the current price as meaningfully below the range of intrinsic value estimates across NAV and income based methods.

🐻 Alexandria Real Estate Equities Bear Case

Fair value: US$50.00

Implied premium to fair value: 6.2%

Revenue growth assumption: 2.67%

• The bearish Narrative anchors on a fair value of US$50.00 per share, which sits close to a trimmed analyst target and treats the stock as roughly in line with what the more cautious analyst cohort expects.
• It focuses on pressure from higher financing costs, potential erosion of demand linked to hybrid work and funding trends in key biotech hubs, and the impact of large impairment charges on reported asset values.
• It frames Alexandria Real Estate Equities as a company where concentration in life science clusters, evolving regulation and ESG requirements and ongoing capital needs could cap upside and keep the shares nearer to the lower end of analyst price targets.

If you want to see how those viewpoints translate into full cash flow paths, assumptions and risk checks, you can review the complete bull and bear Narratives side by side before deciding which story comes closest to your own expectations for Alexandria Real Estate Equities.

See what the community is saying about Alexandria Real Estate Equities

Do you think there’s more to the story for Alexandria Real Estate Equities? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com